The Impact of Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome on Progression of Fibrosis in Patients With Recurrent HCV After Liver Transplantation

Transplantation Proceedings

Volumn 38, Issue 5, 2006, Pages 1440-1444

  Mindikoglu, A L ^a   Regev, A ^a   Casanova Romero, P Y ^a   Bejarano, P A ^a   Martinez, E J ^a   Tzakis, A G ^a   Schiff, E R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DACLIZUMAB; INTERFERON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; RIBAVIRIN; TACROLIMUS;

ADULT; ALCOHOLIC FATTY LIVER; ARTICLE; CALCULATION; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; METABOLIC SYNDROME X; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; SEPSIS; TIME SERIES ANALYSIS; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; BIOPSY; CHOLESTEROL, HDL; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVING DONORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; TRIGLYCERIDES;

EID: 33745217305     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.02.060     Document Type: Article

References (21)

1. Sanyal A.J., Contos M.J., Sterling R.K., et al. Nonalcoholic fatty liver Disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 98 (2003) 2064
2. Adinolfi L.E., Gambardella M., Andreana A., et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33 (2001) 1358
3. Cholet F., Nousbaum J.B., Richecoeur M., et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol 28 (2004) 272
4. Lonardo A., Adinolfi L.E., Loria P., et al. Steatosis and hepatitis C virus. mechanisms and significance for hepatic and extrahepatic disease. Gastroenterol 126 (2004) 586
5. Fartoux-Heyman L., Poupon R., and Serfaty L.D. Impact of steatosis on fibrosis progression in mild hepatitis C. (Abstract). Hepatology 40 suppl 1 (2004) 682A
6. Monto A. Hepatitis C and steatosis. Semin Gastrointest Dis 13 (2002) 40
7. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 106 (2002) 3143
8. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome. report of the national heart, lung and blood institute/American heart association conference on scientific issues related to definition. Circulation 109 (2004) 433
9. Adams L., Abraham S., Angulo P., et al. Are the metabolic syndrome and steatohepatitis risk factors for advanced hepatic fibrosis in patients with hereditary hemochromatosis?. (Abstract). Hepatology 40 suppl 1 (2004) 579A
10. Demetris A.J., Batts K.P., Dhillon A.P., et al. Banff schema for grading liver allograft rejection. an international consensus document. Hepatology 25 (1997) 658
11. Brunt E.M. Nonalcoholic steatohepatitis. Semin Liver Dis 24 (2004) 3
12. Toniutto P., Fabris C., Apollonio L., et al. Excess weight gain after liver transplantation and early fibrosis progression of recurrent hepatitis C. Hepatology 40 suppl 1 (2004) 358A
13. Berenguer M., Ferrell L., Watson J., et al. HCV-related fibrosis progression following liver transplantation. increase in recent years. J Hepatol 32 (2000) 673
14. Chopra K.B., Demetris A.J., Blakolmer K., et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 76 (2003) 1487
15. Wali M., Harrison R.F., Gow P.J., et al. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 51 (2002) 248
16. Neumann U.P., Berg T., Bahra M., et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 41 (2004) 830
17. Machicao V.I., Bonati H., Krishna M., et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 77 (2004) 84
18. Pelletier S.J., Iezzoni J.C., Crabtree T.D., et al. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus. persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 6 (2000) 44
19. Machicao V.I., Krishna M., Bonatti H., et al. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. Liver Transpl 10 (2004) 599
20. Castera L., Hezode C., Roudot-Thoraval F., et al. Worsening of steatosis is an independent risk factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52 (2003) 288
21. Regev A., Berho M., Jeffers L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 (2002) 2614